Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
J Gastroenterol Hepatol. 2022 Mar;37(3):499-506. doi: 10.1111/jgh.15732. Epub 2021 Nov 26.
The prevalence of ulcerative colitis (UC) is increasing in Japan. Validated claims-based definitions are required to investigate the epidemiology of UC and its treatment and disease course in clinical practice. This study aimed to develop a claims-based algorithm for UC in Japan.
A committee of epidemiologists, gastroenterologists, and internal medicine physicians developed a claims-based definition for UC, based on diagnostic codes and claims for UC treatments, procedures (cytapheresis), or surgery (postoperative claims). Claims data and medical records for a random sample of 200 cases per site at two large tertiary care academic centers in Japan were used to calculate the positive predictive value (PPV) of the algorithm for three gold standards of diagnosis, defined as physician diagnosis in the medical records, adjudicated cases, or registration in the Japanese Intractable Disease Registry (IDR).
Overall, 1139 claims-defined UC cases were identified. Among 393 randomly sampled cases (mean age 44; 48% female), 94% had received ≥ 1 systemic treatment (immunosuppressants, tumor necrosis factor inhibitors, corticosteroids, or antidiarrheals), 7% had cytapheresis, and 7% had postoperative claims. When physician diagnosis was used as a gold standard, PPV was 90.6% (95% confidence interval [CI]: 87.7-93.5). PPV with expert adjudication was also 90.6% (95% CI: 87.7-93.5). PPVs with enrollment in the IDR as gold standard were lower at 41.5% (95% CI: 36.6-46.3) due to incomplete case registration.
The claims-based algorithm developed for use in Japan is likely to identify UC cases with high PPV for clinical studies using administrative claims databases.
溃疡性结肠炎(UC)在日本的发病率正在上升。为了研究 UC 的流行病学及其在临床实践中的治疗和疾病进程,需要有经过验证的基于索赔的定义。本研究旨在为日本开发一种基于索赔的 UC 算法。
一个由流行病学家、胃肠病学家和内科医生组成的委员会,根据诊断代码和 UC 治疗、程序(细胞分离术)或手术(术后索赔)的索赔,制定了一个基于索赔的 UC 定义。使用来自日本两家大型三级保健学术中心的每个地点的 200 例随机抽样的索赔数据和病历,计算算法对三种诊断金标准的阳性预测值(PPV),这些金标准定义为病历中的医生诊断、裁决病例或在日本难治性疾病登记处(IDR)中的登记。
总体而言,确定了 1139 例基于索赔的 UC 病例。在 393 例随机抽样病例(平均年龄 44 岁,48%为女性)中,94%接受了≥1 种系统治疗(免疫抑制剂、肿瘤坏死因子抑制剂、皮质类固醇或抗腹泻药),7%接受了细胞分离术,7%有术后索赔。当医生诊断作为金标准时,PPV 为 90.6%(95%置信区间[CI]:87.7-93.5)。专家裁决的 PPV 也为 90.6%(95% CI:87.7-93.5)。由于病例登记不完整,以 IDR 登记为金标准的 PPV 较低,为 41.5%(95% CI:36.6-46.3)。
为日本开发的基于索赔的算法很可能为使用行政索赔数据库的临床研究识别出具有高 PPV 的 UC 病例。